TABLE 4.
Type 11A antibody concentrations in infants before and after boosting with either PncD conjugate vaccine or PS vaccine and in adults before and 1 month after vaccination with PncD/T conjugate or PS vaccine
| Lot no. of PS 11A used in EIA | Vaccinees and vaccine | 11A PS in vaccine | n | GMC of 11A antibody, μg/ml (95% confidence intervals)
|
No. (%) with >2-fold increase in GMC | |
|---|---|---|---|---|---|---|
| Prea | Postb | |||||
| 79268 | Infants | |||||
| PncD | No | 12 | 0.28 (0.16–0.50) | 2.79c (0.96–8.12) | 8 (73) | |
| PS | Yes | 11 | 0.24 (0.18–0.33) | 1.26d (0.60–2.67) | 8 (73) | |
| Adults | ||||||
| PncD/T | No | 10 | 1.32 (0.72–2.41) | 2.38e (1.13–5.03) | 2 (20) | |
| Controlf | No | 12 | 2.69 (1.89–3.82) | 2.67 (1.82–3.90) | 0 (0) | |
| PS | Yes | 10 | 1.38 (0.73–2.61) | 3.82c (1.65–8.87) | 7 (70) | |
| 963596 | Infants | |||||
| PncD | No | 12 | 0.13 (0.06–0.30) | 0.15 (0.07–0.33) | 1 (8) | |
| PS | Yes | 11 | 0.09 (0.06–0.16) | 0.84d (0.37–1.89) | 9 (90) | |
| Adults | ||||||
| PncD/T | No | 10 | 0.88 (0.45–1.71) | 1.45e (0.69–3.07) | 2 (20) | |
| Controlf | No | 12 | 4.20 (2.91–6.07) | 4.02 (2.62–6.17) | 0 (0) | |
| PS | Yes | 10 | 1.18 (0.52–2.69) | 3.03c (1.05–8.70) | 8 (80) | |
For infants, preboost samples were obtained at 14 months; for adults, prevaccination samples were obtained on day zero.
For infants, postboost samples were obtained at 15 months; for adults, postvaccination samples were obtained on day 28.
Difference in GMCs of IgG before and after vaccination or boost is significant (P < 0.01, paired two-sample t test).
Difference in GMCs of IgG before and after vaccination or boost is significant (P < 0.001, paired two-sample t test).
Difference in GMCs of IgG before and after vaccination or boost is significant (P < 0.05, paired two-sample t test).
Control group members (n = 12) had not received any pneumococcal vaccinations.